---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010924"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:06:24.961654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Q4 2022 net loss of $58.4M, including $48.6M goodwill impairment; refocuses on kidney transplant

## Summary
- Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).
- Cash and equivalents $56.4M at Dec 31, 2022; expected to fund operations into Q1 2024.
- Phase 1b kidney transplant trial dosed fourth patient; data on first three to be presented at WCN March 31, 2023.
- Deprioritized IgAN program and discontinued islet cell trial; collaboration with eGenesis for xenotransplantation.
- Subject to financing, Phase 2 BESTOW trial of tegoprubart in kidney transplant expected to initiate mid-2023.

## SEC filing metadata
- accession: 0000950170-23-010924
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/eldn-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010924
- JSON: https://secwatch.observer/filing/0000950170-23-010924.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010924.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income net loss of $88.0 million, or $6.16 per share.
  - Period: the year ended December 31, 2022
  - Net income: net loss of $88.0 million, or $6.16 per share
  - Result: reported results
  source text: The Company reported a net loss of $88.0 million, or $6.16 per share, for the year ended December 31, 2022, compared to a net loss of $34.5 million, or $2.33 per share, in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the four months ended December 31, 2022 results: net income net loss of $58.4 million, or $4.09 per share.
  - Period: the four months ended December 31, 2022
  - Net income: net loss of $58.4 million, or $4.09 per share
  - Result: reported results
  source text: The Company reported a net loss of $58.4 million, or $4.09 per share, for the three months ended December 31, 2022, compared to a net loss of $8.8 million, or $0.59 per share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.